SEC Form 4														
FORM 4 UNIT			D STA	ſES	SSION	OMB APPROVAL								
Section 16. Form 4 or Form 5 obligations may continue. See				l pursua	PF CHANGE ant to Section 16(a ection 30(h) of the l) of the	Securi	ties Exchange		RSHIP OMB Number: 32 Estimated average burden hours per response:				
1. Name and Address of Reporting Person [*] Jakobovits Aya					uer Name and Tick cet <u>Bio, Inc.</u>			Symbol	(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) C/O ADICET	(First) BIO, INC. ON STREET, 13T			te of Earliest Trans 5/2020	action (I	Month	/Day/Year)		Officer (give below)	title Other (specify below)				
(Street) BOSTON	MA (State)	02116 (Zip)		4. If A	Amendment, Date o	f Origina	al File	d (Month/Day/	Year)	Line	e) X Form filed by	Group Filing (Checl y One Reporting Po y More than One R	erson	
		Table I - No	on-Deriva	ative	Securities Aco	quirec	l, Dis	sposed of,	or Ber	neficiall	y Owned			
Date			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)	Acquired (D) (Instr.	(A) or 3, 4 and	5. Amount of Securities Beneficially Owned Followin Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stoc	k		09/15/2	.020		Α		627,812	A	(1)	627,812	I	By grantor retained annuity trusts. ⁽⁴⁾	
Common Stoc	k		09/15/2	.020		A		135,799	A	(2)	135,799	I	By grantor retained annuity trust. ⁽⁵⁾	
Common Stoc	k		09/15/2	.020		A		77,500	A	(3)	77,500	I	By grantor retained irrevocable trust. ⁽⁶⁾	
Common Stoc	k		09/15/2	.020		A		77,500	A	(3)	77,500	I	By grantor retained irrevocable trust. ⁽⁷⁾	
		Table II			ecurities Acqualls, warrants						Owned			

(0.3., pare, care, care, content and coordinate)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$16.11	09/17/2020		A		30,000		(8)	09/16/2030	Common Stock	30,000	\$0.00	30,000	D	

Explanation of Responses:

1. Received in exchange for 5,063,006 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was s[] per share.

2. Received in exchange for 1,095,154 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was s[] per share.

3. Received in exchange for 625,000 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was [] per share.

4. Shares held in a grantor retained annuity trust ("GRAT") of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary.

5. Shares held in a GRAT of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary.

6. Shares held in a trust of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits's child is the beneficiary.

7. Shares held in a trust of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits's child is the beneficiary.

8. The shares of common stock subject to the option shall vest in equal installments on each of the thirty-six (36) monthly anniversaries of the [vesting commencement date], provided that the reporting person remains in continuous service as of the applicable vesting date.

/s/ Nick Harvey, Attorney-in- 09/17/2020 Fact for Aya Jakobovits

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.